Expert warns of thiazolidinedione-related bone loss in diabetes

08/18/2011 | (free registration)

Following the results of several studies, rheumatologist Jonathan Graf has cautioned patients with diabetes to avoid using thiazolidinediones as they appear to reduce bone density and elevate fracture risk. However, taking lower doses of thiazolidinediones in combination with either metformin or incretin drugs may still help patients achieve efficient diabetes control without risking bone health, Graf said.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA